血清肿瘤标志物：临床 TNM 小细胞肺癌患者隐匿性淋巴结转移的潜在指标。
Serum tumor markers: potential indicators for occult lymph node metastasis in clinical TNM small cell lung cancer patients.
机构信息
Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
出版信息
Respir Res. 2024 Sep 16;25(1):341. doi: 10.1186/s12931-024-02941-9.
In their letter-to-the-editor entitled "Letter to the Editor: Incidence rate of occult lymph node metastasis in clinical TNM small cell lung cancer patients and radiomic prediction based on contrast-enhanced CT imaging: a multicenter study", Prof. Chen et al. provided insightful comments and suggestions on our original study. We appreciate the authors' feedback and have conducted a preliminary exploration of the predictive value of serum tumor markers (TMs) for occult lymph node metastasis (OLM) in clinical TNM (cTNM) small cell lung cancer (SCLC) patients. The results indicate that neuron-specific enolase (NSE), carbohydrate antigen 125 (CA125), and squamous cell carcinoma antigen (SCC) have potential predictive value for detecting OLM in cTNM SCLC patients. Additionally, further exploration and confirmation through prospective, large-scale studies with robust external validation are needed.
在题为“致编辑的信：临床 TNM 小细胞肺癌患者隐匿性淋巴结转移的发生率和基于增强 CT 成像的放射组学预测：一项多中心研究”的信函中，Chen 教授等人对我们的原始研究提出了深刻的评论和建议。我们感谢作者的反馈，并对临床 TNM（cTNM）小细胞肺癌（SCLC）患者血清肿瘤标志物（TMs）对隐匿性淋巴结转移（OLM）的预测价值进行了初步探讨。结果表明，神经元特异性烯醇化酶（NSE）、糖抗原 125（CA125）和鳞状细胞癌抗原（SCC）对检测 cTNM SCLC 患者的 OLM 具有潜在的预测价值。此外，还需要通过具有强大外部验证的前瞻性、大规模研究进一步探索和确认。
Zotero 插件